Safety and Immunogenicity of a Plant-Produced Recombinant Hemagglutinin-Based Influenza Vaccine (HAI-05) Derived from A/Indonesia/05/2005 (H5N1) Influenza Virus: A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study in Healthy Adults

Safety and Immunogenicity of a Plant-Produced Recombinant Hemagglutinin-Based Influenza Vaccine (HAI-05) Derived from A/Indonesia/05/2005 (H5N1) Influenza Virus: A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study in Healthy Adults

Recently, we have reported [1,2] on a subunit influenza vaccine candidate based on the recombinant hemagglutinin protein from the A/Indonesia/05/2005 (H5N1) strain of influenza virus, produced it using ‘launch vector’-based transient expression technology in Nicotiana benthamiana, and demonstrated i...

Full description

Bibliographic Details
Main Authors: Brian J. Green, George Moonsammy, Stephen J. Streatfield, Vidadi Yusibov, Fudu Miao, Mark Stow, R. Mark Jones, Jessica A. Chichester
Format: Article
Language:English
Published: MDPI AG 2012-11-01
Series:Viruses
Subjects:
influenza A
H5N1
recombinant vaccine
hemagglutinin
plant-produced vaccine
Online Access:http://www.mdpi.com/1999-4915/4/11/3227

Internet

http://www.mdpi.com/1999-4915/4/11/3227

Similar Items